title: Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma.
abstract: Hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC) incidence in the United States is increasing, partly because of risk factors such as diabetes, fatty liver, hepatitis B virus, and human immunodeficiency virus coinfection. Achieving sustained virologic response (SVR) is the most significant factor in reducing HCV-associated HCC incidence. Improved SVR with the next generation of direct-acting antivirals brings hope for decreased HCC mortality. Nevertheless, surveillance for HCC remains important because HCC can still occur despite SVR, especially in cirrhotics. Individualized risk stratification through increased understanding of HCC pathogenesis and improved surveillance holds the promise for future reduction of HCC incidence.
authors.affiliation: Gastroenterology & Hepatology, Oregon Health & Sciences University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA.
authors.forename: Danielle M
authors.initials: DM
authors.lastname: Tholey
authors.affiliation: Division of Gastroenterology and Hepatology, Oregon Health & Sciences University, 3181 Southwest Sam Jackson Park Road, Mail Code L461, Portland, OR 97239, USA. Electronic address: Ahnj@ohsu.edu.
authors.forename: Joseph
authors.initials: J
authors.lastname: Ahn
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000628:therapy / Q000821:virology*; D003131:Combined Modality Therapy; D016174:Hepacivirus / Q000235:genetics / Q000472:pathogenicity; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000601:surgery / Q000821:virology; D006801:Humans; D015994:Incidence; D008113:Liver Neoplasms / Q000453:epidemiology / Q000628:therapy / Q000821:virology*; D016031:Liver Transplantation; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D000998:Antiviral Agents
keywords: Direct-acting antivirals; Hepatitis C virus; Hepatocellular carcinoma; Liver cancer